Document Report Card

Basic Information

ID: ALA4184154

Journal: Bioorg Med Chem Lett

Title: Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.

Authors: Wang X, Wang Y, Wu J, Gui L, Zhang X, Zheng M, Wang Y, Zhao S, Li Z, Zhao M, Peng S.

Abstract: In GPIIb/IIIa mediated arterial thrombosis platelet activation plays a central role. To discover platelet activation inhibitor the pharmacophores of GPIIb/IIIa receptor inhibitors and anti-thrombotic agents were analyzed. This led to the design of (1R,3S)- and (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acids as GPIIb/IIIa inhibitors. Comparing to (1S,3S)-isomer (1R,3S)-isomer had lower cdocker interaction energy. AFM image showed that the minimal effective concentration of (1S,3S)-isomer and (1R,3S)-isomer inhibiting platelet activation were 10-5 M and 10-6 M, respectively. In vivo 1 μmol/kg of oral (1S,3S)-isomer effectively inhibited the rats to form arterial thrombus and down regulated GPIIb/IIIa expression, but the activities were significantly lower than those of 1 μmol/kg of oral (1R,3S)-isomer. Both (1S,3S)-isomer and (1R,3S)-isomer can be safely used for structural modifications, but (1R,3S)-isomer should be superior to (1S,3S)-isomer.

CiteXplore: 29108753

DOI: 10.1016/j.bmcl.2017.10.068